BHVN Insider Transactions
| Transaction Date (SEC Report ) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2022-10-31 | Coric Vlad | director, officer: Chief Executive Officer | 1,543,394 | P-Purchase | A | 25,800 | 15.97 | 411,995.04 |
| 2022-10-28 | Coric Vlad | director, officer: Chief Executive Officer | 109,565 | P-Purchase | A | 100,000 | 14.82 | 1,482,420.00 |
| 2022-10-28 | Coric Vlad | director, officer: Chief Executive Officer | 1,517,594 | P-Purchase | A | 41,930 | 14.87 | 623,352.34 |
| 2022-10-25 | Coric Vlad | director, officer: Chief Executive Officer | 1,475,664 | P-Purchase | A | 853,380 | 10.50 | 8,960,490.00 |
| 2022-10-25 | Buten Matthew | officer: Chief Financial Officer | 166,653 | P-Purchase | A | 142,857 | 10.50 | 1,499,998.50 |
| 2022-10-25 | CHILDS JOHN W | director | 5,691,251 | P-Purchase | A | 3,900,000 | 10.50 | 40,950,000.00 |
| 2022-10-25 | Bailey Gregory | director | 1,507,971 | P-Purchase | A | 200,000 | 10.50 | 2,100,000.00 |
| 2022-10-25 | GREGORY JULIA P | director | 25,665 | P-Purchase | A | 9,523 | 10.50 | 99,991.50 |
| 2022-10-05 | Coric Vlad | director, officer: Chief Executive Officer | 399,443 | P-Purchase | A | 2,100 | 12.35 | 25,928.07 |
| 2022-10-05 | Coric Vlad | director, officer: Chief Executive Officer | 397,343 | P-Purchase | A | 52,523 | 11.79 | 619,162.13 |
| 2022-10-05 | Coric Vlad | director, officer: Chief Executive Officer | 344,820 | P-Purchase | A | 80,606 | 10.82 | 871,907.04 |
| 2022-10-05 | Coric Vlad | director, officer: Chief Executive Officer | 264,214 | P-Purchase | A | 34,459 | 9.89 | 340,968.36 |
| 2022-10-05 | Coric Vlad | director, officer: Chief Executive Officer | 229,755 | P-Purchase | A | 73,005 | 8.82 | 644,130.42 |
| 2022-10-05 | Coric Vlad | director, officer: Chief Executive Officer | 492,212 | P-Purchase | A | 54,329 | 11.83 | 642,614.28 |
| 2022-10-05 | Coric Vlad | director, officer: Chief Executive Officer | 437,883 | P-Purchase | A | 80,907 | 10.83 | 875,842.55 |
| 2022-10-05 | Coric Vlad | director, officer: Chief Executive Officer | 356,976 | P-Purchase | A | 34,515 | 9.90 | 341,843.46 |
| 2022-10-05 | Coric Vlad | director, officer: Chief Executive Officer | 322,461 | P-Purchase | A | 73,331 | 8.82 | 647,028.75 |
| 2022-10-05 | CHILDS JOHN W | director | 1,791,251 | P-Purchase | A | 32,841 | 9.70 | 318,403.35 |
| 2022-10-05 | CHILDS JOHN W | director | 1,758,410 | P-Purchase | A | 241,300 | 8.88 | 2,142,768.13 |
| 2022-10-03 | Conway Charles | officer: Chief Scientific Officer | 0 | D-Return | D | 54,000 | 9.07 | 489,780.00 |
| 2022-10-03 | Conway Charles | officer: Chief Scientific Officer | 0 | D-Return | D | 54,000 | 9.07 | 489,780.00 |
| 2022-10-03 | Conway Charles | officer: Chief Scientific Officer | 0 | D-Return | D | 54,000 | 9.07 | 489,780.00 |
| 2022-10-03 | Antonijevic Irina | director | 0 | D-Return | D | 5,070 | 0.00 | 0.00 |
| 2022-10-03 | Engelhart James | officer: Strategic Advisor | 0 | D-Return | D | 83,792 | 9.07 | 759,993.44 |
| 2022-10-03 | Engelhart James | officer: Strategic Advisor | 0 | D-Return | D | 83,792 | 9.07 | 759,993.44 |
| 2022-10-03 | Engelhart James | officer: Strategic Advisor | 0 | D-Return | D | 83,792 | 9.07 | 759,993.44 |
| 2022-10-03 | Engelhart James | officer: Strategic Advisor | 0 | D-Return | D | 83,792 | 9.07 | 759,993.44 |
| 2022-10-03 | Tilton John | officer: Chief Commercial Officer | 0 | D-Return | D | 37,292 | 9.07 | 338,238.44 |
| 2022-10-03 | Tilton John | officer: Chief Commercial Officer | 0 | D-Return | D | 37,292 | 9.07 | 338,238.44 |
| 2022-10-03 | Tilton John | officer: Chief Commercial Officer | 0 | D-Return | D | 37,292 | 9.07 | 338,238.44 |
| 2022-10-03 | Tilton John | officer: Chief Commercial Officer | 1,614 | D-Return | D | 5,068 | 148.50 | 752,598.00 |
| 2022-10-03 | GREGORY JULIA P | director | 0 | D-Return | D | 18,000 | 60.24 | 1,084,320.00 |
| 2022-10-03 | Mehta Kishan | director | 0 | D-Return | D | 20,000 | 36.64 | 732,800.00 |
| 2022-10-03 | Mehta Kishan | director | 0 | D-Return | D | 20,000 | 36.64 | 732,800.00 |
| 2022-10-03 | Mehta Kishan | director | 0 | D-Return | D | 20,000 | 36.64 | 732,800.00 |
| 2022-10-03 | Buten Matthew | officer: Chief Financial Officer | 0 | D-Return | D | 22,900 | 125.69 | 2,878,301.00 |
| 2022-10-03 | Buten Matthew | officer: Chief Financial Officer | 0 | D-Return | D | 22,900 | 125.69 | 2,878,301.00 |
| 2022-10-03 | Buten Matthew | officer: Chief Financial Officer | 0 | D-Return | D | 22,900 | 125.69 | 2,878,301.00 |
| 2022-10-03 | Heffernan Michael Thomas | director | 0 | D-Return | D | 26,200 | 47.30 | 1,239,260.00 |
| 2022-10-03 | Heffernan Michael Thomas | director | 0 | D-Return | D | 26,200 | 47.30 | 1,239,260.00 |
| 2022-10-03 | Heffernan Michael Thomas | director | 15,178 | F-InKind | D | 9,699 | 7.50 | 72,742.50 |
| 2022-10-03 | HUGIN ROBERT J | director | 12,959 | F-InKind | D | 12,959 | 7.50 | 97,192.50 |
| 2022-10-03 | Coric Vlad | director, officer: Chief Executive Officer | 569,309 | J-Other | A | 0 | 0.00 | 0.00 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 300,000 | A-Award | A | 300,000 | 7.00 | 2,100,000.00 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 0 | M-Exempt | A | 12,500 | 0.54 | 6,750.00 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 0 | M-Exempt | A | 12,500 | 0.54 | 6,750.00 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 0 | M-Exempt | A | 12,500 | 0.54 | 6,750.00 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 12,500 | J-Other | A | 12,500 | 0.54 | 6,750.00 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 4,500 | J-Other | A | 4,500 | 1.86 | 8,370.00 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 20,716 | J-Other | A | 20,716 | 1.03 | 21,337.48 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 295 | J-Other | A | 295 | 1.03 | 303.85 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 1,542 | J-Other | A | 1,542 | 1.61 | 2,482.62 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 30,958 | J-Other | A | 30,958 | 1.61 | 49,842.38 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 3,000 | J-Other | A | 3,000 | 2.52 | 7,560.00 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 14,000 | J-Other | A | 14,000 | 2.84 | 39,760.00 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 13,801 | J-Other | A | 13,801 | 4.13 | 56,998.13 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 1,199 | J-Other | A | 1,199 | 4.13 | 4,951.87 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 12,612 | J-Other | A | 12,612 | 6.37 | 80,338.44 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 387 | J-Other | A | 387 | 6.37 | 2,465.19 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 95,969 | F-InKind | D | 37,492 | 7.00 | 262,444.00 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 133,461 | M-Exempt | A | 12,500 | 0.54 | 6,750.00 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 120,961 | M-Exempt | A | 4,500 | 1.86 | 8,370.00 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 116,461 | M-Exempt | A | 20,716 | 1.03 | 21,337.48 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 95,745 | M-Exempt | A | 295 | 1.03 | 303.85 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 95,450 | M-Exempt | A | 1,542 | 1.61 | 2,482.62 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 93,908 | M-Exempt | A | 30,958 | 1.61 | 49,842.38 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 62,950 | M-Exempt | A | 3,000 | 2.52 | 7,560.00 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 59,950 | M-Exempt | A | 14,000 | 2.84 | 39,760.00 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 45,950 | M-Exempt | A | 13,801 | 4.13 | 56,998.13 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 32,149 | M-Exempt | A | 1,199 | 4.13 | 4,951.87 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 30,950 | M-Exempt | A | 12,612 | 6.37 | 80,338.44 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 18,338 | M-Exempt | A | 387 | 6.37 | 2,465.19 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 17,951 | J-Other | A | 1,875 | 0.00 | 0.00 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 16,076 | J-Other | A | 3,750 | 0.00 | 0.00 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 12,326 | J-Other | A | 6,500 | 0.00 | 0.00 |
| 2022-10-03 | Gentile Kimberly | officer: SVP, Clinical Operations | 5,826 | J-Other | A | 5,826 | 0.00 | 0.00 |
| 2022-10-03 | Heffernan Michael Thomas | director | 125,000 | A-Award | A | 125,000 | 7.00 | 875,000.00 |
| 2022-10-03 | Heffernan Michael Thomas | director | 0 | M-Exempt | A | 13,100 | 2.40 | 31,440.00 |
| 2022-10-03 | Heffernan Michael Thomas | director | 13,100 | J-Other | A | 13,100 | 2.40 | 31,440.00 |
| 2022-10-03 | Heffernan Michael Thomas | director | 5,998 | J-Other | A | 5,998 | 3.56 | 21,352.88 |
| 2022-10-03 | Heffernan Michael Thomas | director | 4,119 | J-Other | A | 4,119 | 4.84 | 19,935.96 |
| 2022-10-03 | Heffernan Michael Thomas | director | 19,370 | F-InKind | D | 5,507 | 7.50 | 41,302.50 |
| 2022-10-03 | Heffernan Michael Thomas | director | 24,877 | M-Exempt | A | 13,100 | 2.40 | 31,440.00 |
| 2022-10-03 | Heffernan Michael Thomas | director | 11,777 | M-Exempt | A | 5,998 | 3.56 | 21,352.88 |
| 2022-10-03 | Heffernan Michael Thomas | director | 5,779 | M-Exempt | A | 4,119 | 4.84 | 19,935.96 |
| 2022-10-03 | Heffernan Michael Thomas | director | 1,660 | J-Other | A | 1,660 | 0.00 | 0.00 |
| 2022-10-03 | CHILDS JOHN W | director | 5,000 | J-Other | A | 5,000 | 0.00 | 0.00 |
| 2022-10-03 | CHILDS JOHN W | director | 1,517,110 | J-Other | A | 1,512,500 | 0.00 | 0.00 |
| 2022-10-03 | Coric Vlad | director, officer: Chief Executive Officer | 9,565 | J-Other | A | 9,565 | 0.00 | 0.00 |
| 2022-10-03 | Coric Vlad | director, officer: Chief Executive Officer | 156,750 | J-Other | A | 156,750 | 0.00 | 0.00 |
| 2022-10-03 | Coric Vlad | director, officer: Chief Executive Officer | 249,130 | J-Other | A | 249,130 | 0.00 | 0.00 |
| 2022-10-03 | Coric Vlad | director, officer: Chief Executive Officer | 622,284 | J-Other | A | 46,025 | 0.00 | 0.00 |
| 2022-10-03 | CHILDS JOHN W | director | 0 | D-Return | D | 11,996 | 70.17 | 841,759.32 |
| 2022-10-03 | CHILDS JOHN W | director | 0 | D-Return | D | 11,996 | 70.17 | 841,759.32 |
| 2022-10-03 | HUGIN ROBERT J | director | 0 | D-Return | D | 18,948 | 66.88 | 1,267,242.24 |
| 2022-10-03 | HUGIN ROBERT J | director | 0 | D-Return | D | 18,948 | 66.88 | 1,267,242.24 |
| 2022-10-03 | HUGIN ROBERT J | director | 0 | D-Return | D | 18,948 | 66.88 | 1,267,242.24 |
| 2022-10-03 | JONES WILLIAM A JR | officer: CCO-Migraine & Common Disease | 0 | D-Return | D | 44,087 | 49.47 | 2,180,983.89 |
| 2022-10-03 | JONES WILLIAM A JR | officer: CCO-Migraine & Common Disease | 0 | D-Return | D | 44,087 | 49.47 | 2,180,983.89 |
| 2022-10-03 | JONES WILLIAM A JR | officer: CCO-Migraine & Common Disease | 0 | D-Return | D | 44,087 | 49.47 | 2,180,983.89 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Group doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Group or anyone involved with Discounting Cash Flows Group will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.